Two-year Data: PsA Patients Taking Bimekizumab-bkzx (Bimzelx, UCB) Show Sustained Improvements
New two-year data showed sustained improvements in clinical and patient-reported outcomes in active psoriatic arthritis (PsA) among patients treated with bimekizumab-bkzx (Bimzelx, UCB). These findings will be highlighted at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. Bimekizumab-bkzx received FDA approval for PsA, non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in Sept. 2024. The interleukin […]